$VVOS SEC Filings

Granted 12,000 Stock Options (Right to Buy)

Granted 12,000 Stock Options (Right to Buy)

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

This Assignment and Co-Ownership Agreement (this “Agreement”) is entered into as of the Closing Date under the Mutual Stock Purchase and Asset Exchange Agreement dated as of October 14, 2026 (as subsequently amended on October 15, 2026 a...

Certain exhibits and schedules to this Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the U.S. Securities and Exchang...

We have read the statements made by Vivos Therapeutics, Inc. included under Item 4.01(a) of its Current Report on Form 8-K dated September 30, 2026 to be filed with the Securities and Exchange Commission. We agree with the statements con...

Granted 12,000 Stock Options (Right to Buy)

Granted 12,000 Stock Options (Right to Buy)

Acquired 85,910 shares (Other Transaction) ($50K) · Acquired 85,910 Warrant (Right to Buy) (Other Transaction) ($50K)

As previously reported, the Company previously sold and issued to Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”), a Secured Promissory Note with an original issuance date of June 9, 2025 in the original pr...

As previously reported, Vivos Therapeutics, Inc. (the “Company”) previously sold and issued to Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”), a Secured Promissory Note with an original issuance date of Ju...

Received 250,000 shares as a grant or award ($103K) · Granted 150,000 Stock Option (Right to Buy) ($61.5K)